Abstract
INTRODUCTION
Severe mitral regurgitation (MR) is a frequent indication for valve surgery [1] . For primary (i.e. degenerative) regurgitation, mitral valve repair (MVR) is widely accepted as the preferred treatment over valve replacement, whereas the approach for secondary (i.e. functional) MR remains controversial [2] .
In 1987, Levine et al. [3] described the saddle shape of the mitral valve (MV) annulus, which led to the design of annuloplasty rings matching this shape. Subsequent studies have shown that restoring the native shape and function of the mitral annulus reduces leaflet strain and improves leaflet coaptation [4] [5] [6] [7] [8] . This article reports findings from a multicentre observational study of MVR using a rigid, saddle-shaped ring in patients with MR.
MATERIALS AND METHODS

Study design
The Expertise-based Assessment Study on clinical Efficacy of Profile 3D in MITRAL valve annuloplasty (EASE MITRAL) was a prospective, non-randomized, observational, postmarket release study performed to collect clinical data about the Profile 3D MV annuloplasty ring (Medtronic, Minneapolis, MN, USA). The ring received the Conformité Europé ene mark and US Food and Drug Administration clearance in 2008, and it was in commercial use in the countries in which the study was conducted. The study was designed to enrol 150 patients with ischaemic or non-ischaemic MR in 10-15 centres in Europe, Canada and Saudi Arabia.
The study was conducted in compliance with the Declaration of Helsinki and the laws and regulations of each country, including data protection laws. The study was approved by the ethics committee or institutional review board at each centre. Patients and physicians provided signed data release forms, the use of which was approved by each centre.
Device description
The Profile 3D ring is an asymmetrical, non-planar, rigid annuloplasty ring that consists of a titanium core overmoulded with silicone and covered in polyester fabric. The ring is saddle-shaped, similar to the native MV annulus (Fig. 1) . It is marked at 3 points by coloured sutures; 2 markers correspond to the trigons of the MV and 1 indicates the midpoint of the ring. Device size is measured by the inner diameter of the ring at its widest point. The titanium core enables radiographic visualization of the device. The study ring is compatible with magnetic resonance imaging (normal mode).
Study objectives and outcome measures
The study had 3 primary end points: (i) to identify the patient population for which the Profile 3D annuloplasty ring was chosen to repair MV insufficiency, (ii) to assess the percentage of patients who achieved chronic relief from MV dysfunction (defined as no dysfunction at the 6-12-month follow-up visit) and (iii) to determine the level of MR in patients at 6-12 months postimplant. Patient characteristics collected preoperatively included age, gender, previous cardiovascular surgery, symptoms of heart failure, cardiac rhythm, New York Heart Association (NYHA) classification, risk factors, level of regurgitation and type of MV deficiency. Procedural details were collected at the time of implant. Echocardiography was performed preoperatively, at discharge and at the 6-12-month follow-up visit to assess the relief of MV dysfunction. Two-dimensional Doppler echocardiography was used to determine the level of MR at the follow-up visit. The levels of MR were defined as follows (the percentage of the regurgitant fraction is in parentheses): Level 0, none (0%); Level 1, mild (<20%); Level 2, moderate (20-39%); Level 3, moderate to severe (40-59%) and Level 4, severe (> _60%). Only the level of regurgitation, and not the specific percentage of regurgitant flow, was determined for this end point to reduce variability in the evaluation of echocardiographic data.
Secondary end points included the number of stand-alone MVR procedures, patient health status (i.e. heart failure symptoms, cardiac rhythm, NYHA classification and risk factors) at the 6-12-month follow-up visit and level of MR preoperatively. In addition, we determined the degree of downsizing (count and percentage) of the mitral annulus during the procedure and documented adverse events (AEs) through the 6-12-month follow-up visit.
Study population
Patients aged 18-85 years with moderate-to-severe MR at rest (i.e. Level 2 or higher) were eligible for enrolment. Patients with ischaemic or non-ischaemic MR were allowed. Patients with heavily calcified valves, valvular retraction with severely reduced mobility, active bacterial endocarditis or life expectancy <1 year were excluded. Additional exclusion criteria were participation in another device study, current pregnancy or desire to become pregnant within 12 months postimplant.
Statistical analysis
A 1-sided, 1-sample exact test for binomial proportions was used to evaluate the null hypothesis that the proportion of implanted subjects with no or mild MR at 6-12 months postimplant would be at least 85%. The lower bound of the 2-sided 90% confidence interval was also provided. The null hypothesis would be rejected if the P-value from the 1-sided, 1-sample exact test for binomial proportions was <0.05.
For continuous variables, means and standard deviations are presented. Frequencies and percentages are presented for categorical variables.
For sample size calculation, it was assumed that an approximately equal distribution of patients with ischaemic and non-ischaemic MR would be enrolled. It was further assumed that 92% of the patients intended and attempted to be implanted would receive the study ring and that 8% of patients would not receive the ring (e.g. due to the need for valve replacement). Also, it was expected that approximately 15% of patients would withdraw from the study for various reasons. With these assumptions, the final sample size was calculated to be 150 (75 Â 2) patients.
However, less than 20% of enrolled patients had ischaemic MR preoperatively. Ad hoc analyses were performed among patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) preoperatively. These summaries included level of MR, number and rate of deaths and NYHA class among this subgroup of patients at 6-12 months postimplant.
RESULTS
Between 27 February 2013 and 9 July 2015, 151 patients were enrolled at 7 centres in Europe and Canada. No patients were enrolled in Saudi Arabia. Of enrolled patients, data for 2 patients were excluded from analysis because they were consented late. One patient was enrolled but withdrew before the preoperative evaluation, leaving 148 patients in the enrolled cohort; of them, 147 patients underwent attempted implant. Figure 2 provides details about patient disposition during the study. One hundred thirty-eight of 139 patients (99.3%) completed the discharge visit, and 139 (100.0%) underwent echocardiography at this time. One hundred twenty-five of 126 patients (99.2%) completed the follow-up visit, and 113 of 126 (89.7%) underwent echocardiography.
Patient characteristics
In the enrolled cohort (n = 148), the mean age of the patients was 63.8 ± 12.3 years, and 85 patients (57.4%) were men. The dominant cardiac rhythm was sinus rhythm in 87 patients (58.8%) and atrial fibrillation (AF) in 45 patients (30.4%). Twenty-one patients (14.2%) had undergone a previous cardiovascular surgery. Eighty-two patients (56.6%) were in NYHA Class III or IV. Risk factors included systemic hypertension in 80 (54.1%) patients, coronary artery disease in 37 (25.0%) patients and a history of congestive heart failure in 31 (20.9%) patients (Table 1 ). Barlow's disease was present in 55 patients (37.2%) and fibroelastic deficiency in 40 patients (27.0%). ICM was present in 15 patients (10.1%), and DCM was present in 12 patients (8.1%). MR was severe in 86 patients (59.3%). Additional preoperative characteristics are listed in Table 1 . Characteristics of patients who underwent attempted implant (n = 147) are included in the Supplementary Material, Table S1 .
Procedural characteristics
Among patients who underwent attempted implant (n = 147), the surgical approach was standard sternotomy in 85 patients (57.8%), right minithoracotomy in 60 patients (40.8%), ministernotomy in 1 (0.7%) and thoracotomy in 1 (0.7%). One patient undergoing minithoracotomy had an intra-aortal balloon occlusion during the procedure and was converted to a standard 
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sternotomy. The most frequent MV pathologies were mitral annulus dilatation, which was observed in 106 patients (72.1%), prolapse, which was observed in 88 patients (59.9%) and ruptured chordae, which were observed in 62 patients (42.2%). The mean implanted ring size was 32.9 ± 3.6 mm. The Supplementary Material, Table S2 , provides the distribution of implanted ring sizes. Annular downsizing was performed in 36 of 135 patients (26.7%).
Stand-alone MVR was performed in 5 of the 147 patients who underwent attempted implant (3.4%). Ninety-four patients (63.9%) underwent a concomitant procedure at the time of repair. Coronary artery bypass grafting was performed in 24 patients (16.3%) with a mean number of 2.0 ± 1.0 grafts. Treatment for AF was performed in 47 patients (32.0%) and included radiofrequency ablation (5 of 47, 10.6%), cryoablation (40 of 47, 85.1%) and other procedures (2 of 47, 4.3%). Additional concomitant procedures are listed in the Supplementary Material, Table S2 .
Implantation of the study ring was successful in 141 of 147 patients (95.9%). In 4 patients (2.7%), the procedure was converted to MV replacement. For 2 of these patients, no reason was specified, and 1 had a pathology (unspecified) identified during the operation that made reconstruction impossible. One patient had leaflet billowing; after an unsuccessful attempt to implant a different ring, MV replacement was performed. Two additional patients (1.4%) received a different device for anatomical reasons (1 Barlow MV disease and 1 unspecified).
Relief from mitral valve dysfunction at 6-12 months
The mean follow-up time postimplant was 236.2 ± 109.9 days. One hundred five of 113 patients with an assessable echocardiogram (92.9%) had no or mild MR at the 6-12-month follow-up visit. The lower bound of the 2-sided 90% confidence interval was 87.6% (P = 0.008), supporting rejection of the null hypothesis. Figure 3 shows MR at the preoperative and the follow-up visits among patients with data available at both time points (n = 111). The percentage of patients with no or mild MR increased from 0.0% preoperatively to 94.5% (105/111) at follow-up. MR was improved in 110 (99.1%) of these patients and unchanged in 1 patient (0.9%). No patients had worsening of MR postimplant. Cardiac rhythm and New York Heart Association class Figure 4 shows cardiac rhythm at the preoperative and follow-up visits among patients with data available at both time points (n = 115). The percentage of patients in sinus rhythm increased from 58.3% to 81.7%, and the percentage with AF decreased from 29.6% to 5.2% following MVR with the study ring. Figure 5 shows NYHA class at the preoperative and 6-12-month visits among patients with data available at both time points (n = 109). The percentage of patients with NYHA Class I increased from 16.5% at the preoperative visit to 79.8% at follow-up. Change in NYHA class was available for 112 of 125 patients who completed the follow-up visit. Improvement in NYHA class occurred in 82 of these patients (73.2%). There was no change in 25 patients (22.3%), and worsening occurred in 2 patients (1.8%).
Ischaemic and dilated cardiomyopathy
Of the 27 patients with preoperative ICM or DCM, 1 died 5 days postimplant. At the follow-up visit, 83.3% of patients were in NYHA Class I or II and 84.2% had no or mild MR (Fig. 6) .
Adverse events
Among patients who underwent attempted implant (n = 147), there were 3 deaths during the study (1 cardiac and 2 non-cardiac). Two deaths (1.4%) occurred within 30 days postimplant, and 1 death (0.7%) occurred >30 days postimplant. All 3 deaths were considered possibly related to the implant procedure. Two minor stroke or cerebrovascular events occurred in 2 patients (1.4%) within 30 days postimplant. One patient had 1 major and 1 minor stroke or cerebrovascular event >30 days postimplant. There were 2 explants. One explant was due to ring dehiscence. The ring was torn from the patient's tissue in the anterior area, which was frail, and central mitral insufficiency developed. The ring had been correctly implanted and was still intact at explant. The other explant was due to early recurrence of mitral insufficiency (2 of 4) in a patient with Barlow disease and systolic anterior motion of the MV. Both patients underwent MV replacement. AF occurred postoperatively in 25 of 147 patients who underwent attempted implant (17.0%). Among these 25 patients, AF was the dominant preoperative cardiac rhythm in 6. Five of these patients received concomitant ablation during MVR. At discharge, AF remained the dominant cardiac rhythm in 3 of these patients, and 1 of those 3 patients remained in AF at both discharge and follow-up. The rest of the patients did not have AF as the dominant cardiac rhythm at either discharge or follow-up. Pleural effusions occurred in 15 of 147 patients who underwent attempted implant (10.2%). Rates of other AEs were low (Table 2) . Details about serious, device-related and procedure-related AEs are provided in the Supplementary Material, Tables S3-S5.
DISCUSSION
The results of this study demonstrate low rates of death and other AEs, and marked improvement in degree of MR and NYHA class, in patients 6-12 months after MVR with the Profile 3D annuloplasty ring. Ad hoc subgroup analyses showed favourable outcomes in patients with ICM or DCM, which are associated with a poorer prognosis than non-ischaemic MR [9] .
Three deaths occurred among the 151 enrolled patients during follow-up of 6-12 months. This number compares favourably with the findings of Guenzinger et al. [10] , who reported 3 early deaths (i.e. within 30 days, 1.5%) and 7 additional deaths during 2.5 ± 0.5 years of follow-up among 200 patients who received the Profile 3D ring for degenerative MR. Acker et al. [11] , in a randomized comparison of repair versus replacement for severe ischaemic MR, reported 2 early deaths (within 30 days, 1.6%) and an additional 18 deaths (14.3%) among 126 MVR patients during 12 months of follow-up. In our study, the most common AE was AF, which was observed in 17.0% of patients who underwent attempted implant. AF is relatively common in patients with MR, and patients with AF made up nearly one-third of our study population. Indeed, its development in patients with MR is an indication for valve repair because of its association with lower rates of survival and late stroke [12] . Major haemorrhage occurred in 3.4%, and major stroke and minor stroke occurred in 0.7% and 2.0%, respectively.
In a paired analysis, MR improved from the preoperative visit to the follow-up visit at 6-12 months. At follow-up, 94.6% had no or mild MR, compared with 0.0% at the preoperative visit. Four patients (3.6%) had moderate MR, 2 (1.8%) had moderate-to-severe MR and none had severe MR. Improvement was observed in 99.1% of patients, unchanged in 1 (0.9%) and worsened in none. These findings are in line with those of Guenzinger et al. [10] , who reported no or mild MR in 93.1% (mean follow-up of 1.0 ± 0.6 years postimplant), moderate MR in 4.4%, moderate-to-severe MR in 2.5% and no severe MR among patients with degenerative MR. In our patients with ICM or DCM, 84.2% of patients had no or mild MR, 10.5% had moderate MR, 5.3% had moderate-to-severe MR and none had severe MR following MVR. Our findings in patients with ischaemic MR differ from those of Acker et al. [11] , who reported recurrence of moderate MR in 28.4% and severe MR in 4.2% of patients with ischaemic MR at 12 months of follow-up.
We can only speculate about why our follow-up rates for moderate-to-severe MR were lower than rates observed in the MVR cohort of Acker et al. [11] because the number of ischaemic patients in our study was much lower (26 vs 251) and because we did not collect the same echocardiographic details. Nonetheless, one possibility may be study population. Acker et al. conducted a randomized comparison of MV replacement versus repair among patients with severe ischaemic MR and coronary artery disease. In this non-randomized observational study of MVR, 60% of patients had severe MR, 28% had moderate-to-severe MR and 25% had coronary artery disease preoperatively. Another possible explanation may be the saddle-shaped design of the annuloplasty ring. In the Acker et al. study, surgeons were allowed to select the type of annuloplasty ring, and the only requirements were that the ring was an approved, complete, rigid or semirigid annuloplasty ring. The shape of rings used (planar or non-planar) was not described. In our study, only a complete, non-planar, saddle-shaped ring was used. Saddle-shaped annuloplasty rings have been demonstrated to improve leaflet coaptation, prevent additional annular dilatation and increase leaflet curvature following MVR [4, [6] [7] [8] [13] [14] [15] . These effects help to reduce stress on the valve components [16] , which may have the potential to improve the efficacy and durability of MVR and may have contributed to the reduced rate of MR observed in our study.
Improvements in cardiac rhythm and NYHA class from the preoperative visit to the follow-up visit were substantial, with the percentage of patients in sinus rhythm increasing from 58.3% preoperatively to 81.7% at follow-up. The percentage of patients in NYHA Class I or II doubled from 47.7% preoperatively to 95.4% at follow-up. Among patients with ICM or DCM, 83.3% of patients were in NYHA Class I or II at follow-up.
Limitations
The findings of this study should be interpreted with caution in light of the following limitations. The total enrolment of this study was 151, with 147 patients undergoing attempted implant and 125 completing the 6-12-month follow-up visit. In addition, only 26 patients with ICM or DCM were enrolled and available for the subgroup analyses. The study was observational and included no randomization or comparison with other treatments for MR. Echocardiograms were analysed by individuals at participating institutions instead of by a core laboratory. Finally, the study was conducted at multiple centres, which may differ in standard practice and surgeon experience.
CONCLUSIONS
These findings indicate that MVR using the Profile 3D annuloplasty ring is a safe and effective treatment for MR. Further investigation, ideally in randomized controlled trial, is warranted to determine whether patients with ICM or DCM derive unique benefit from this saddle-shaped ring.
